Anticoagulant News and Research

RSS

NIH-funded study to evaluate rescue medications for victims of toxic gases

National Jewish Health researchers have received nearly $13 million from the National Institutes of Health to evaluate potential rescue medications for victims of terrorist attacks, wartime use of toxic gases, and/or inhalation disasters. The gases of greatest interest in these studies will be 'mustard gas' (sulfur mustard) and chlorine gas.

14 Oct 2011

New AAOS guideline recommends how to reduce DVT, PE after joint replacement surgery

An updated clinical practice guideline released last week by the American Academy of Orthopaedic Surgeons (AAOS) Board of Directors recommends how to reduce the likelihood of blood clots after hip or knee replacement surgery, procedures that more than 800,000 Americans undergo each year. The new guideline suggests use of preventive treatments and advises against routinely screening patients after surgery using ultrasound imaging.

1 Oct 2011

Study calls for review of current treatment strategies, more research into stroke prevention

Doctors are underutilising crucial medication to prevent deadly strokes in those with a common type of heart condition, new research says, leading to fresh calls for a review of current treatment strategies and more research into stroke prevention.

1 Oct 2011

Review of stroke treatment could save lives

29 Sep 2011

EMA CHMP adopts positive opinion for Soliris to treat atypical hemolytic uremic syndrome

Alexion Pharmaceuticals, Inc. today announced that the European Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending that the therapeutic indication for Soliris® (eculizumab) be extended to include the treatment of pediatric and adult patients with atypical hemolytic uremic syndrome (aHUS) in Europe.

23 Sep 2011

Encouraging results from Alexion's eculizumab Phase 2 study on generalized myasthenia gravis

Alexion Pharmaceuticals, Inc. today announced that the Company's study of eculizumab in a small group of 14 patients with severe and refractory generalized myasthenia gravis, an ultra-rare and debilitating form of generalized myasthenia gravis (gMG), showed a strong disease improvement signal.

15 Sep 2011

Low-dose aspirin increases risk for GI bleeding

The risk of gastrointestinal (GI) bleeding needs to be considered when determining the potential preventive benefits associated with low-dose aspirin for cardiovascular disease and cancer.

12 Sep 2011

Alchemia initiates HA-Irinotecan Phase II clinical study in SCLC

Alchemia Limited, today announced the initiation of recruitment for a Phase II clinical study of its lead cancer drug HA-Irinotecan in Small Cell Lung Cancer (SCLC). Two patients have received their first doses of therapy. This investigator sponsored trial is being conducted at Monash Cancer Centre, Southern Health and Peninsula Oncology Centre in Melbourne, Victoria.

12 Sep 2011

Cardiovascular and Renal Drugs Advisory Committee recommends FDA approval of J&JPRD's rivaroxaban

Johnson & Johnson Pharmaceutical Research and Development, L.L.C. (J&JPRD) announced today that the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee recommended approval of rivaroxaban, a novel, once-daily, oral anticoagulant, for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.

9 Sep 2011

Results of darexaban phase II trial in recent acute coronary syndrome presented at ESC Congress

A phase II dose-finding study has found that the new oral Factor Xa inhibitor darexaban was associated with a two to four-fold increase in bleeding when added to dual antiplatelet therapy in patients following an acute coronary syndrome.

30 Aug 2011

Bristol Meyer Squibb’s new blood thinner drug for stroke prevention

Researchers find that an experimental anticlotting pill Eliquis is more effective than standard drug, warfarin, at preventing strokes in people with a heart condition that puts them at high risk of blood clots and stroke. The new drug also known as apixaban, cut the risk of stroke by 21% compared with warfarin in people with atrial fibrillation (AF). It lowered the risk of dying by 11%.

30 Aug 2011

Dabigatran etexilate superior to warfarin for stroke prevention in AF patients

New data from two RE-LY trial sub-group analyses show that dabigatran etexilate provides consistent benefits in stroke in atrial fibrillation (AF) compared to well-controlled warfarin, irrespective of whether patients use antiplatelet or other concomitant therapies, such as the anti-arrhythmics amiodarone or verapamil.

29 Aug 2011

One in three AF patients at high risk of stroke are not being prescribed VKA therapy

New data show that, worldwide, one in three patients with atrial fibrillation (AF) who are at high risk for stroke are not being prescribed anticoagulant therapy, particularly vitamin K antagonists (VKA) – medicines known to significantly lower stroke risk in these patients.

29 Aug 2011

ELIQUIS better than warfarin in reduction of stroke, major bleeding, and mortality

Bristol-Myers Squibb Company and Pfizer Inc. today announced the main results of the Phase 3 clinical trial ARISTOTLE, which evaluated ELIQUIS compared to warfarin for the prevention of stroke or systemic embolism in 18,201 patients with atrial fibrillation and at least one risk factor for stroke.

29 Aug 2011

Apixaban superior to warfarin in preventing stroke and systemic embolism

A large-scale trial finds that apixaban, a new anticoagulant drug, is superior to the standard drug warfarin for preventing stroke and systemic embolism in patients with atrial fibrillation.

29 Aug 2011

BIPI to launch dabigatran etexilate Phase II trial in patients with mechanical heart valves

Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced plans to launch RE-ALIGN, a global, Phase II trial evaluating the safety and pharmacokinetics of dabigatran etexilate in 400 patients who have mechanical heart valves.

26 Aug 2011

ICU patients less likely to renew prescriptions for chronic diseases after discharge

Patients often do not renew prescriptions for their chronic diseases after they are released from hospital.

25 Aug 2011

New technique can detach sugars from carrier molecule, reattach them to drugs

The surface of cells and many biologically active molecules are studded with sugar structures that are not used to store energy, but rather are involved in communication, immunity and inflammation.

22 Aug 2011

Anticoagulation service improves quality of care for patients treated with warfarin

A pharmacist-directed anticoagulation service improves the coordination of care from the hospital to an outpatient clinic for patients treated with the anticoagulant drug warfarin, according to a Henry Ford Hospital study.

11 Aug 2011

ESC to produce focused update on AF Guidelines following early termination of PALLAS Trial

The Guidelines Department of the European Society of Cardiology has issued the following statement today: "The European Society of Cardiology (ESC) is aware of the early termination of the PALLAS trial because of adverse outcomes associated with dronedarone.

5 Aug 2011

Anticoagulant News and Research

NIH-funded study to evaluate rescue medications for victims of toxic gases

New AAOS guideline recommends how to reduce DVT, PE after joint replacement surgery

Study calls for review of current treatment strategies, more research into stroke prevention

Review of stroke treatment could save lives

EMA CHMP adopts positive opinion for Soliris to treat atypical hemolytic uremic syndrome

Encouraging results from Alexion's eculizumab Phase 2 study on generalized myasthenia gravis

Low-dose aspirin increases risk for GI bleeding

Alchemia initiates HA-Irinotecan Phase II clinical study in SCLC

Cardiovascular and Renal Drugs Advisory Committee recommends FDA approval of J&JPRD's rivaroxaban

Results of darexaban phase II trial in recent acute coronary syndrome presented at ESC Congress

Bristol Meyer Squibb’s new blood thinner drug for stroke prevention

Dabigatran etexilate superior to warfarin for stroke prevention in AF patients

One in three AF patients at high risk of stroke are not being prescribed VKA therapy

ELIQUIS better than warfarin in reduction of stroke, major bleeding, and mortality

Apixaban superior to warfarin in preventing stroke and systemic embolism

BIPI to launch dabigatran etexilate Phase II trial in patients with mechanical heart valves

ICU patients less likely to renew prescriptions for chronic diseases after discharge

New technique can detach sugars from carrier molecule, reattach them to drugs

Anticoagulation service improves quality of care for patients treated with warfarin

ESC to produce focused update on AF Guidelines following early termination of PALLAS Trial

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News